Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Sulphasalazine in ulcerative colitis.

Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p = 0.03, trend in proportions). The higher ...

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

One hundred and sixty four patients with ulcerative colitis in remission were entered into a double blind, double dummy trial comparing olsalazine 500 mg bd and sulphasalazine 1 g bd. Clinical examination, sigmoidoscopy and rectal biopsy were performed at 0, three, and six months. Sixteen of 82 (19.5%) patients relapsed on olsalazine and 10/82 (12.2%) relapsed on sulphasalazine. The difference ...

Controlled Trial of Sulphasalazine in the Treatment of Ulcerative Colitis.

EDITORIAL SYNOPSIS This paper provides further evidence that sulphasalazine is an effective agent in the treatment of mild or moderate colitis. There was a high incidence of gastrointestinal side-effects and one patient developed haemolytic anaemia. Sulphasalazine (salicylazosulphapyridine, Salazo-pyrin, Asulfidine) was first used by Svartz (1942) in the treatment of rheumatoid arthritis. Later...

Optimum dose of olsalazine for maintaining remission in ulcerative colitis

To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p=0.03, trend in proportions). The higher do...